MSCs for Gastrointestinal Disorders

  • Maria Ester Bernardo
  • Angela Maria Cometa
  • Franco Locatelli
Chapter
Part of the Stem Cell Biology and Regenerative Medicine book series (STEMCELL)

Abstract

Recent experimental findings and clinical trials have shown the ability of mesenchymal stromal cells (MSCs) to home to damaged tissues and to produce paracrine factors with anti-inflammatory properties, resulting in reduction of inflammation and functional recovery of the damaged tissues. These properties, in the context of regenerative medicine, are being tested in chronic inflammatory disorders of the gastrointestinal (GI) tract. Phase I–II clinical trials indicate that intravenous and local injection of ex vivo-expanded MSCs are feasible and safe in luminal and fistulizing Crohn’s Disease (CD) and in end-stage liver diseases. Large randomized clinical trials are warranted to properly establish the role of MSC therapy for these diseases, in comparison with conventional treatment. This chapter focuses on recent research on the anti-inflammatory/reparative properties of MSCs and discusses the potential clinical applications of MSC-based cellular therapy in GI disorders.

Keywords

Toxicity Prostaglandin Luminal Sponge Dextran 

Notes

Acknowledgment

This work has been partly supported by grants from Istituto Superiore di Sanità (National Program on Stem Cells), MIUR (Ministero dell’Istruzione, dell’Università e della Ricerca, Progetti di Rilevante Interesse Nazionale, PRIN), from Associazione Italiana per la Ricerca sul Cancro (AIRC) special grant “5 × 1,000” to FL, and from AIRC IG9062 to MEB.

References

  1. 1.
    Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP (1968) Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6:230–247PubMedCrossRefGoogle Scholar
  2. 2.
    Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Lurià EA, Ruadkow IA (1974) Precursors for fibroblast in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 2:83–92PubMedGoogle Scholar
  3. 3.
    Nourissat G, Diop A, Maurel N, Salvat C, Dumont S, Pigenet A et al (2010) Mesenchymal stem cell therapy regenerates the native bone-tendon junction after surgical repair in a degenerative rat model. PLoS One 5:e12248PubMedCrossRefGoogle Scholar
  4. 4.
    Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A et al (2001) Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 344:385–386PubMedCrossRefGoogle Scholar
  5. 5.
    Haleem AM, Singergy AA, Sabry D, Atta HM, Rashed LA, Chu CR et al (2010) The clinical use of human culture-expanded autologous bone marrow mesenchymal stem cells transplanted on platelet-rich fibrin glue in the treatment of articular cartilage defects: a pilot study and preliminary results. Cartilage 1:253–261PubMedCrossRefGoogle Scholar
  6. 6.
    Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M et al (1999) Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5:309–313PubMedCrossRefGoogle Scholar
  7. 7.
    Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM et al (2007) Co-transplantation of ex-vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem cell transplantation. Blood 110:2764–2767PubMedCrossRefGoogle Scholar
  8. 8.
    Bernardo ME, Ball LM, Cometa AM, Roelofs H, Zecca M, Avanzini MA et al (2011) Co-infusion of ex vivo expanded, parental mesenchymal stromal cells prevents life-threatening acute GvHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 46:200–207PubMedCrossRefGoogle Scholar
  9. 9.
    Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579–1586PubMedCrossRefGoogle Scholar
  10. 10.
    Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E et al (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106:1755–1761PubMedCrossRefGoogle Scholar
  11. 11.
    Lee RH, Seo MJ, Pulin AA, Gregory CA, Ylostalo J, Prockop DJ (2006) Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/SCID mice. Proc Natl Acad Sci USA 103:17438–17443PubMedCrossRefGoogle Scholar
  12. 12.
    Jurewicz M, Yang S, Augello A, Godwin JG, Moore RF, Azzi J et al (2010) Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes 59:3139–3147PubMedCrossRefGoogle Scholar
  13. 13.
    Morigi M, Rota C, Montemurro T, Montelatici E, Lo Cicero V, Imberti B et al (2010) Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. Stem Cells 28:513–522PubMedGoogle Scholar
  14. 14.
    van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW, Yarmush ML (2008) Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 47:1634–1643PubMedCrossRefGoogle Scholar
  15. 15.
    Duijvenstein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW et al (2010) Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut 59:1662–1669CrossRefGoogle Scholar
  16. 16.
    González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M (2009) Adipose-derived ­mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 136:978–989PubMedCrossRefGoogle Scholar
  17. 17.
    Hayashi Y, Tsuji S, Tsujii M, Nishida T, Ishii S, Iijima H et al (2008) Topical implantation of mesenchymal stem cells has beneficial effects on healing of experimental colitis in rats. J Pharmacol Exp Ther 326:523–531PubMedCrossRefGoogle Scholar
  18. 18.
    Zhang Q, Shi S, Liu Y, Uyanne J, Shi Y, Shi S, Le AD (2009) Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol 183:7787–7798PubMedCrossRefGoogle Scholar
  19. 19.
    Yabana T, Arimura Y, Tanaka H, Goto A, Hosokawa M, Nagaishi K et al (2009) Enhancing epithelial engraftment of rat mesenchymal stem cells restores epithelial barrier integrity. J Pathol 218:350–359PubMedCrossRefGoogle Scholar
  20. 20.
    Hayashy Y, Tsuji S, Tsuji M, Nishida T, Ishii S, Iijima H et al (2008) Topical transplantation of mesenchymal stem cells accelerates gastric ulcer healing in rats. Am J Physiol Gastrointest Liver Physiol 294:778–786CrossRefGoogle Scholar
  21. 21.
    Hori Y, Nakamura T, Kimura D, Kaino K, Kurokawa Y, Satomi S, Shimizu Y (2002) Experimental study on tissue engineering of the small intestine by mesenchymal stem cell seeding. J Surg Res 102:156–160PubMedCrossRefGoogle Scholar
  22. 22.
    Sirbu-Boeti MP, Chivu M, Paslaru LL, Efrimescu C, Herlea V, Pecheanu C et al (2009) Transplantation of mesenchymal stem cells cultured on biomatrix support induces repairing of digestive tract defects in animal model. Chirurgia 104:55–65PubMedGoogle Scholar
  23. 23.
    Zhang J, Gong JF, Zhang W, Zhu WM, Li JS (2008) Effects of transplanted bone marrow mesenchymal stem cells on the irradiated intestine of mice. J Biomed Sci 15:585–594PubMedCrossRefGoogle Scholar
  24. 24.
    Mouiseddine M, François S, Semont A, Sache A, Allenet B, Mathieu N et al (2007) Human mesenchymal stem cells home specifically to radiation-injured tissues in a non-obese diabetes/severe combined immunodeficiency mouse model. Br J Radiol 80:S49–S55PubMedCrossRefGoogle Scholar
  25. 25.
    Lorenzi B, Pessina F, Lorenzoni P, Urbani S, Vernillo R, Sgaragli G et al (2008) Treatment of experimental injury of anal sphincters with primary surgical repair and injection of bone marrow-derived mesenchymal stem cells. Dis Colon Rectum 51:411–420PubMedCrossRefGoogle Scholar
  26. 26.
    Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K et al (2009) Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15:42–49PubMedCrossRefGoogle Scholar
  27. 27.
    Tanaka F, Tominaga K, Ochi M, Tanigawa T, Watanabe T, Fujiwara Y et al (2008) Exogenous administration of mesenchymal stem cells ameliorates dextran sulphate-sodium-induced colitis via anti-inflammatory action in damaged tissue in rats. Life Sci 83:771–779PubMedCrossRefGoogle Scholar
  28. 28.
    Wei Y, Nie Y, Lai J, Wan Y-J, Li Y (2009) Comparison of the population capacity of hematopoietic and mesenchymal stem cells in experimental colitis rat model. Transplantation 88:42–48PubMedCrossRefGoogle Scholar
  29. 29.
    Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R (2003) Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 101:2999–3001PubMedCrossRefGoogle Scholar
  30. 30.
    Wynn RF, Hart CA, Corradi-Perini C, O’Neill L, Evans CA, Wraith JE et al (2004) A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 104:2643–2645PubMedCrossRefGoogle Scholar
  31. 31.
    Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T et al (2005) Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 106:419–427PubMedCrossRefGoogle Scholar
  32. 32.
    Fox JM, Chamberlain G, Ashton BA, Middleton J (2007) Recent advances into the understanding of mesenchymal stem cell trafficking. Br J Haematol 137:491–502PubMedCrossRefGoogle Scholar
  33. 33.
    Larghero J, Farge D, Braccini A, Lecourt S, Scherberich A, Foïs E et al (2008) Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis 67:443–449PubMedCrossRefGoogle Scholar
  34. 34.
    Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R et al (2007) Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology 46:403–408PubMedCrossRefGoogle Scholar
  35. 35.
    Bernardo ME, Avanzini MA, Ciccocioppo R, Perotti C, Cometa AM, Moretta A et al (2009) Phenotypical/functional characterization of in vitro expanded mesenchymal stromal cells from Crohn’s disease patients. Cytotherapy 11:825–836PubMedCrossRefGoogle Scholar
  36. 36.
    Osiris Therapeutics I (2007) Evaluation of PROCHYMAL[tm] adult human stem cells for treatment-resistant moderate-to-severe Crohn’s disease. www.clinicaltrials.gov. NCT00482092 ed
  37. 37.
    Taupin P (2006) OTI-010 Osiris therapeutics/JCR pharmaceuticals. Curr Opin Investig Drugs 7:473–481PubMedGoogle Scholar
  38. 38.
    García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA (2005) A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 48:1416–1423PubMedCrossRefGoogle Scholar
  39. 39.
    Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J et al (2009) Expanded adipose-tissue derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 52:79–86PubMedCrossRefGoogle Scholar
  40. 40.
    Garcia-Olmo D, Herreros D, De-La-Quintana P, Guadalajara H, Trébol J, Georgiev-Hristov T, García-Arranz M et al (2010) Adipose-derived stem cells in Crohn’s rectovaginal fistula. Case Report Med 2010:961758PubMedGoogle Scholar
  41. 41.
    Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C et al (2011) Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut 60:788–798PubMedCrossRefGoogle Scholar
  42. 42.
    Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H et al (2007) Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med 10:459–466PubMedGoogle Scholar
  43. 43.
    Kharaziha P, Hellström PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F et al (2009) Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol 21:1199–1205PubMedCrossRefGoogle Scholar
  44. 44.
    Lazebnik LB, Konopliannikov AG, Kniazev OV, Parfenov AI, Tsaregorodtseva TM, Ruchkina IN et al (2010) Use of allogeneic mesenchymal stem cells in the treatment of intestinal inflammatory diseases. Ter Arkh 82:38–43PubMedGoogle Scholar
  45. 45.
    Lazebnik LB, Guseĭn-Zade MG, Kniazev OV, Efremov LI, Ruchkina IN (2010) Pharmaco-economic benefits of patients with ulcerative colitis treatment with help of mesenchymal stem cells. Eksp Klin Gastroenterol 3:51–59PubMedGoogle Scholar
  46. 46.
    Cho JH (2008) The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 8:458–466PubMedCrossRefGoogle Scholar
  47. 47.
    Kamm MA, Ng SC (2008) Perianal fistulizing Crohn’s disease: a call to action. Clin Gastroenterol Hepatol 6:7–10PubMedCrossRefGoogle Scholar
  48. 48.
    Garcia-Arranz M, Gomez-Pinedo U, Hardisson D, Herreros D, Guadalajara H, García-Gómez I et al (2010) Histopathological analyses of human specimens removed from the injection area of expanded adipose-derived stem cells. Histopathology 56:968–982CrossRefGoogle Scholar
  49. 49.
    Mohamadnejad M, Namiri M, Bagheri M, Hashemi SM, Ghanaati H, Zare Mehrjardi N et al (2007) Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World J Gastroenterol 13:3359–3363PubMedGoogle Scholar
  50. 50.
    Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM et al (2007) Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 110:1362–1369PubMedCrossRefGoogle Scholar
  51. 51.
    Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H et al (2010) Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 115:1549–1553PubMedCrossRefGoogle Scholar
  52. 52.
    Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J et al (2008) The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22:593–599PubMedCrossRefGoogle Scholar
  53. 53.
    di Bonzo LV, Ferrero I, Cravanzola C, Mareschi K, Rustichell D, Novo E et al (2008) Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut 57:223–231PubMedCrossRefGoogle Scholar
  54. 54.
    Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F et al (2006) The bone marrow functionally contributes to liver fibrosis. Gastroenterology 130:1807–1821PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Maria Ester Bernardo
    • 1
  • Angela Maria Cometa
    • 1
  • Franco Locatelli
    • 2
    • 3
  1. 1.Dipartimento di Ematologia ed Oncologia PediatricaIRCCS Ospedale Pediatrico Bambino GesùRomeItaly
  2. 2.Department of Pediatric Hematology/OncologyIRCCS Bambino Gesù Children’s HospitalRomeItaly
  3. 3.University of PaviaPaviaItaly

Personalised recommendations